AcelRx Pharmaceuticals receives Complete Response Letter from the FDA for DSUVIA™ NDA
AcelRx Pharmaceuticals announced it received a CRL from the FDA regarding its NDA for DSUVIA™ (sufentanil sublingual tablet), 30 mcg. The CRL states that the FDA determined it cannot approve the NDA in its present form and provides recommendations needed for resubmission. October 12, 2017